Talbot Financial LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Talbot Financial LLC grew its position in Pfizer Inc. (NYSE:PFE) by 3.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 305,202 shares of the biopharmaceutical company’s stock after purchasing an additional 10,735 shares during the quarter. Talbot Financial LLC’s holdings in Pfizer were worth $8,833,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Bellevue Group AG increased its holdings in shares of Pfizer by 139.3% during the fourth quarter. Bellevue Group AG now owns 22,868 shares of the biopharmaceutical company’s stock valued at $658,000 after acquiring an additional 13,313 shares in the last quarter. Wasatch Advisors LP increased its stake in Pfizer by 21.0% during the 4th quarter. Wasatch Advisors LP now owns 167,300 shares of the biopharmaceutical company’s stock valued at $4,817,000 after purchasing an additional 29,000 shares in the last quarter. MGO One Seven LLC raised its holdings in shares of Pfizer by 43.0% in the fourth quarter. MGO One Seven LLC now owns 120,715 shares of the biopharmaceutical company’s stock worth $3,475,000 after buying an additional 36,316 shares during the last quarter. Icon Wealth Advisors LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $479,000. Finally, Jacobi Capital Management LLC grew its holdings in shares of Pfizer by 3.3% during the fourth quarter. Jacobi Capital Management LLC now owns 120,810 shares of the biopharmaceutical company’s stock valued at $3,478,000 after buying an additional 3,904 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lifted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Barclays increased their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday, October 3rd. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Trading Down 0.1 %

Shares of PFE stock opened at $29.18 on Wednesday. The stock’s fifty day moving average is $29.14 and its two-hundred day moving average is $28.33. The firm has a market capitalization of $165.35 billion, a P/E ratio of -486.33, a PEG ratio of 1.23 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the company posted $0.67 EPS. The business’s revenue was up 2.1% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.